Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatment of serious acne in adults and teenagers; BTX 1702 that is in Phase 1b/2 clinical trial to treat papulopustular rosacea; BTX 1204A for treating atopic dermatitis; and BTX 1801, which has been completed Phase 2a clinical trial for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus. The company was incorporated in 1984 and is based in Melbourne, Australia.
Frequently asked questions
What sector does Botanix Pharmaceuticals Limited (BXPHF) operate in?
Botanix Pharmaceuticals Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Botanix Pharmaceuticals Limited (BXPHF) current stock price?
As of the latest data, Botanix Pharmaceuticals Limited stock price is $0.01, with a previous close of $0.01.
What is Botanix Pharmaceuticals Limited (BXPHF) current market capitalization?
Botanix Pharmaceuticals Limited market cap is approximately 21.82 million.
What is Botanix Pharmaceuticals Limited (BXPHF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Botanix Pharmaceuticals Limited (BXPHF) EBITDA?
Botanix Pharmaceuticals Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -35.64 million.
Does Botanix Pharmaceuticals Limited (BXPHF) pay dividends?
No. Botanix Pharmaceuticals Limited does not pay a dividend.
What is Botanix Pharmaceuticals Limited (BXPHF) beta (volatility) score?
Botanix Pharmaceuticals Limited has a beta of 0.856, meaning its volatility is roughly in line with the market.
